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Abstract
Background: Giant cell tumor is an infrequent and unpredictable bony lesion. Although numerous attempts have 
been made to predict the behaviour of GCT, there are no definite biological or histological parameters to determine 
the prognosis or aggressiveness of this lesion
Materials and methods: We analyzed Ki 67 immuno-histochemistry of 31 consecutive cases staged III giant cell tumor 
to determine the clinico-pathological correlation. There were 19 male patients compare to 12 females. The mean age 
was 33.8 years ranged from 18 to 59 years. Five cases presented with local recurrence prior to wide resection and one 
case had multiple recurrences there after. Six cases had pulmonary metastases. Expression of Ki 67 antigen was 
evaluated by immuno-histochemical staining techniques using the avidin-biotin perioxidase complex method using 
an LSAB2 kit (Dako, Glostrup, Denmark). The primary antibody used in this study was Ki-67 (MIB-I clone, dilution 1:25; 
Dako).
Results: The mean value of Ki-67 index obtained as a percentage of 1000 background cells was 8.15 (ranged 1.00 - 
20.0). The median Ki 67 index was 7.5 with standard deviation of 5.12. The Ki 67 index of recurrence tumor was 4.323 
compared to 6.05 without recurrence and was not statistically significant (mean difference of 0.865 with p value in 
independent t test of 0.736). The Ki 67 index was also not statistically significant in the presence of pulmonary 
metastases with the mean value of metastases group of 6.681 compared to 2.890 without metastases (mean difference 
of 1.895 with p value in independent t test of 0.424).
Conclusion: Ki 67 index is not use-full prognostic marker for aggressive type of giant cell tumor of the bone.
Background
Giant cell tumor (GCT) of the bone is an infrequent and
unpredictable bony lesion [1]. Although numerous
attempts have been made to predict the behaviour of
GCT, there are no definite biological or histological
parameters to determine the prognosis or aggressiveness
of this lesion [2]. Aggressive lesions (stage III Cam-
panacci) are common in oriental population, and they
have been shown to have higher risk of recurrence and
pulmonary metastases [3-5].
Ki-67 represents a nuclear protein forming part of
DNA replicase complex that provides a simple, rapid and
reliable means of evaluating the growth fraction of neo-
plastic cell populations [6]. Ki-67 was shown to correlate
with the biological behaviour and risk of pulmonary
metastases in a few reported cases of GCT of the bone
[7]. However; there are no reported studies to identify the
effectiveness of this marker to correlate with the aggres-
siveness and prognosis of the disease.
The aim of this study is to identify the effectiveness of
Ki-67 as prognostic marker and in predicting the risk of
local recurrence and pulmonary metastases for aggres-
sive (stage III) GCT of the bone.
Methods
Thirty-one consecutive patients with histologically
proven giant cell tumor, seen at our institution between
January 1999 and December 2006, were included. The
clinical and radiological records of all the patients were
reviewed. Tissue diagnosis and immuno-histopathologi-
cal study was obtained in all cases from the surgical spec-
imen. Stage III or aggressive GCT in this study is defined
as symptomatic, rapidly growing lesion. Bone scans
showed intense activity that often extended beyond the
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lytic area on radiograph and magnetic resonance imaging
showed infiltration of the surrounding soft tissue, which
was confirmed histologically by tumor that has breached
the cortex and extended into the surrounding soft tissue.
There were 19 males and 12 females patents. The mean
age was 33.8 years with range from 18 to 59 years. Eleven
GCT were located at the proximal tibia followed by 9,
involving distal femur, 4 distal radius, 2 distal ulna and
one each at the proximal femur, sacrum, metacarpal, dis-
tal tibia and proximal humerus. All cases were stage III
based on Campanacci staging system3. All cases were
treated with wide resection margin. The surgical speci-
mens were evaluated for microscopic extent of tumor at
the margins and intramedullary marrow extension, and
all were found clear of extension. Five cases presented
with local recurrence prior to wide resection and one
case had multiple recurrences thereafter. Six cases had
pulmonary metastases during follow up, two of which
underwent surgical resection and four had chemother-
apy.
Evaluation of Ki-67 immuno-histochemical expression
Expression of Ki-67 antigen was evaluated by immuno-
histochemical staining in all representative sections from
each patient. Serial sections, 5 μm thick, were cut and
immuno-histochemical techniques were carried out
using the avidin-biotin perioxidase complex method
using an LSAB2 kit (Dako, Glostrup, Denmark). The pri-
mary antibody used in this study was Ki-67 (MIB-I clone,
dilution 1:25; Dako). Expression of proliferation index
marker Ki-67 in the nuclear area of the tumor cells were
examined using immuno-histochemistry. The labeled-
cell count (Ki-67 proliferation index) was determined in
ten high-power fields by two blinded observers. Ki-67
proliferation index was defined as the ratio of labeled
cells to total cells.
Statistical analysis
All data obtained were analysed by using SPSS 12.0.1
software. Statistical analysis between different group
were determined using independent t-test and consid-
ered statistically significant when the p values were less
than 0.05.
Results
The staining was confined to the nuclei of the stromal
cells in all cases. The mean value of Ki-67 index obtained
as a percentage of 1000 background cells was 8.15 (range
1.00 - 20.0). The median Ki-67 index was 7.5 with stan-
dard deviation of 5.12. The Ki-67 index of recurrent
tumor was 4.323 as compared to 6.05 without recurrence
and was not statistically significant (mean difference of
0.865 with 0.736 of p value in independent t test). The Ki-
67 index was also not statistically significant in those with
pulmonary metastases with the mean value of 6.68 with
metastatic group as compared to 2.89 of those without
metastases (mean difference of 1.895 with 0.424 of p
value in independent t test).
In the recurrent tumors with pulmonary metastasis, Ki-
67 index was 6.40 when compared with 2.20 in disease
free cases. The mean difference was 2.099 with p value of
0.326 and was not statistically significant.
Discussion
Stage III or aggressive giant cell tumor is defined as
symptomatic, rapidly growing lesion that is often associ-
ated with spontaneous fracture [2,3]. GCT is an infre-
quent and unpredictable bony lesion, and in our series it
was not only presented with locally aggressive behaviour,
Figure 1 Photomicrograph shows Ki-67 immuno-histochemical 
stain (×100). Ki-67 labeling in brown is limited to the nuclei of mono-
nuclear stromal cells. The proliferative index was 8.
Figure 2 Photomicrograph shows the Ki-67 of a patient with ag-
gressive GCT of the distal femur and multiple pulmonary metas-
tases. Despite aggressive clinical behaviour, the Ki-67 index was 2.Ismail et al. Journal of Experimental & Clinical Cancer Research 2010, 29:25
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but it also had higher incidence of local recurrent and
pulmonary metastasis [4,5].
Various proliferation markers had been studied to cor-
relate with the aggressive behaviour of GCT and surgical
outcome. These included the expression of Ki 67, prolif-
erating cell nuclear antigen, p 53 tumor suppressor gene,
matrix metalloproteinase (MMP)-1/9, parathyroid hor-
mone-like protein (PTH-LP) in the mononuclear histio-
cytic stromal cell. The observations may suggest that
mononuclear histiocytic stromal cells are induced by sev-
eral cytokines acting in an autocrine or paracrine fashion,
which are closely related to the biologic aggressiveness of
GCT [8-10]. However, most of the studies compared the
overall stage of GCT, which were variable in their clinical
behaviour. There was no study to quantify the value of
proliferative markers in stage III GCT and correlate sta-
tistically with the risk of pulmonary metastases. Our
series suggest that the Ki-67 index in aggressive type of
GCT varies significantly with range between 1.00 to
20.00.
The Ki-67 antigen is a human nuclear protein used as a
marker for cellular proliferation. The expression is strictly
associated with cellular proliferation and is widely used in
routine pathological evaluation as a proliferation marker
to measure the growth fraction of cells in human tumors.
Ki-67 antigen is expressed during the G1, S, G2 and M
phases of the cell cycle within the nucleus but is not
expressed during the G0 (resting) phase, and thus it is a
widely accepted proliferation marker and is useful in pre-
dicting the development of human neoplasm [6]. Ki-67
has a short half-life, hence it can be used as a marker for
actively proliferating cells. Since it is not expressed during
the resting phase of a cell cycle, it functions as a specific
indicator of cellular proliferation. Ki-67 antigen immuno-
histochemistry studies have shown that it is confined to
the nuclei of mononuclear cells and there was no labeling
of the multinucleated giant cells. This confirms that GCT
results from proliferation of mononuclear cells and it is in
agreement with our finding in this series that the antigen
is confined to the mononuclear stromal cells in all cases.
Earlier reports if increase in Ki-67 index in recurrent
GCT may indicate that recurrent GCT are more aggres-
sive than the primary tumor [7-10]. In this study the
mean value of Ki-67 index of stage III GCT was 8.15. The
mean value of Ki-67 index was found to be statistically
not significant when tested against the risk of pulmonary
metastases and recurrence disease. This was not in agree-
ment with other studies that showed correlation of Ki-67
with aggressiveness of the lesion. (Figure 1) This implies
that the proliferative marker Ki-67 may not be useful to
predict the risk for tumor recurrent or lung metastases.
(Figure 2)
Conclusion
Ki-67 immuno-pathological marker was not a useful
marker to predict the risk of recurrence and pulmonary
metastases in aggressive giant cell tumor.
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